Philippe Ryvlin, MD, PhD
(Unit 301)
|
Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvelle/Angelini. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB pharma. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini pharma. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB pharma. The institution of Dr. Ryvlin has received research support from Swiss National Fund. The institution of Dr. Ryvlin has received research support from European Commission (Horizon Europe). |